1. Home
  2. PPBT vs JAGX Comparison

PPBT vs JAGX Comparison

Compare PPBT & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBT
  • JAGX
  • Stock Information
  • Founded
  • PPBT 2010
  • JAGX 2013
  • Country
  • PPBT Israel
  • JAGX United States
  • Employees
  • PPBT N/A
  • JAGX N/A
  • Industry
  • PPBT Biotechnology: Pharmaceutical Preparations
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PPBT Health Care
  • JAGX Health Care
  • Exchange
  • PPBT Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • PPBT 6.5M
  • JAGX 7.4M
  • IPO Year
  • PPBT N/A
  • JAGX N/A
  • Fundamental
  • Price
  • PPBT $2.27
  • JAGX $5.88
  • Analyst Decision
  • PPBT Strong Buy
  • JAGX
  • Analyst Count
  • PPBT 1
  • JAGX 0
  • Target Price
  • PPBT $33.00
  • JAGX N/A
  • AVG Volume (30 Days)
  • PPBT 286.5K
  • JAGX 247.5K
  • Earning Date
  • PPBT 05-23-2025
  • JAGX 05-15-2025
  • Dividend Yield
  • PPBT N/A
  • JAGX N/A
  • EPS Growth
  • PPBT N/A
  • JAGX N/A
  • EPS
  • PPBT N/A
  • JAGX N/A
  • Revenue
  • PPBT N/A
  • JAGX $11,689,000.00
  • Revenue This Year
  • PPBT N/A
  • JAGX $22.41
  • Revenue Next Year
  • PPBT N/A
  • JAGX $30.00
  • P/E Ratio
  • PPBT N/A
  • JAGX N/A
  • Revenue Growth
  • PPBT N/A
  • JAGX 19.75
  • 52 Week Low
  • PPBT $2.00
  • JAGX $4.02
  • 52 Week High
  • PPBT $20.60
  • JAGX $502.50
  • Technical
  • Relative Strength Index (RSI)
  • PPBT 40.43
  • JAGX 37.09
  • Support Level
  • PPBT $2.18
  • JAGX $5.30
  • Resistance Level
  • PPBT $2.41
  • JAGX $13.20
  • Average True Range (ATR)
  • PPBT 0.20
  • JAGX 1.49
  • MACD
  • PPBT -0.01
  • JAGX -0.57
  • Stochastic Oscillator
  • PPBT 27.96
  • JAGX 7.30

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: